支架:骨质疏松靶向药物递送的生物材料工程
本文是一篇综述,阐述支架作为药物递送系统在骨质疏松靶向治疗中的作用。骨质疏松治疗分为抗骨吸收和促骨形成两类,支架可实现高载药量并将活性药物递送至特定部位,维持治疗水平。
要点
- 骨质疏松治疗分为抗骨吸收和促骨形成两类。
- 支架是药物递送系统之一,可实现高载药量并向特定部位递送药物。
- 支架能将以可接受的治疗水平保留活性药物。
核心结论
- 本综述旨在阐明支架在骨组织靶向药物递送治疗骨质疏松中的作用。
研究设计与样本
- 本文为综述,目的是阐述支架在骨组织靶向药物递送治疗骨质疏松中的作用。
主要发现
- 骨质疏松是一种日益常见的疾病,导致骨密度低、骨质多孔和骨折风险增加。
- 骨质疏松治疗分为抗骨吸收和促骨形成两类。
- 为减少药物副作用及多次连续给药导致的剂量水平变化,多种药物递送系统被提出。
- 支架是药物递送系统之一,可实现高载药量并向特定部位高效递送药物,使活性药物维持在可接受的治疗水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is an increasingly common condition that causes low bone density, porous bone, and increased fracture risk. Treatments for osteoporosis are divided into two categories: (a) antiresorptive and (b) anabolic. To decrease side effects of drug and dosage level variations caused by several consecutive administrations, various drug delivery systems have been proposed. Among them, scaffolds are one of the drug delivery systems that led to drug impart with high loading and suitable efficiency to specific sites which retain active agents at acceptable therapeutic levels. The purpose of this review was to explain the role of scaffolds in targeted drug delivery to bone tissue for the treatment of osteoporosis.
引用
- Poorirani S, Taheri SL, Mostafavi SA, et al. Scaffolds: a biomaterial engineering in targeted drug delivery for osteoporosis. Osteoporos Int. 2022. PMID: 36241849. doi:10.1007/s00198-022-06543-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。